Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 343

1.

[Costs of chronic obstructive pulmonary disease in patients treated in ambulatory care in Poland].

Jahnz-Różyk K, Targowski T, From S, Faluta T, Borowiec L.

Pneumonol Alergol Pol. 2011;79(5):337-42. Polish.

2.
3.

[Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].

Jahnz-Rózyk K, Targowski T, From S.

Pol Merkur Lekarski. 2009 Mar;26(153):208-14. Polish.

PMID:
19388534
4.

Cost analysis of chronic obstructive pulmonary disease in a tertiary care setting in Taiwan.

Chiang CH.

Respirology. 2008 Sep;13(5):689-94. doi: 10.1111/j.1440-1843.2008.01308.x. Epub 2008 May 29.

PMID:
18513247
6.

[Retrospective analysis of direct costs of hospital treatment of chronic obstructive pulmonary disease exacerbations].

Jahnz-Rózyk K, Targowski T, From S, Płusa T.

Pol Merkur Lekarski. 2004 May;16 Suppl 1:91-4. Polish.

PMID:
15524028
7.

The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review.

Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS.

COPD. 2010 Jun;7(3):214-28. doi: 10.3109/15412555.2010.481697. Review.

PMID:
20486821
8.

Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.

Pasquale MK, Sun SX, Song F, Hartnett HJ, Stemkowski SA.

Int J Chron Obstruct Pulmon Dis. 2012;7:757-64. doi: 10.2147/COPD.S36997. Epub 2012 Nov 1.

9.

Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.

Simoni-Wastila L, Blanchette CM, Qian J, Yang HW, Zhao L, Zuckerman IH, Pak GH, Silver H, Dalal AA.

Am J Geriatr Pharmacother. 2009 Oct;7(5):262-70. doi: 10.1016/j.amjopharm.2009.11.003.

PMID:
19948302
10.

Economic burden of chronic obstructive pulmonary disease.

Teo WS, Tan WS, Chong WF, Abisheganaden J, Lew YJ, Lim TK, Heng BH.

Respirology. 2012 Jan;17(1):120-6. doi: 10.1111/j.1440-1843.2011.02073.x.

PMID:
21954985
11.

The burden of COPD in Spain: results from the Confronting COPD survey.

Izquierdo JL.

Respir Med. 2003 Mar;97 Suppl C:S61-9.

PMID:
12647944
12.

[Estimation of direct medical costs of chronic obstructive pulmonary disease over 12 months].

Stâmbu I, Stoicescu IP.

Pneumologia. 2013 Mar-Jun;62(2):86-92. Romanian.

PMID:
23894789
13.
14.

[Evaluation of clinical effectiveness and direct costs of azithromycin treatment for exacerbation of chronic obstructive pulmonary disease in hospitalized patients and ambulatory care].

Faber M, Jahnz-Rózyk K, Kucharczyk A, Targowski T, From S, Mamełka B.

Pol Merkur Lekarski. 2004 May;16 Suppl 1:96-9. Polish.

PMID:
15524029
15.

The cost of treating patients with COPD in Denmark--a population study of COPD patients compared with non-COPD controls.

Bilde L, Rud Svenning A, Dollerup J, Baekke Borgeskov H, Lange P.

Respir Med. 2007 Mar;101(3):539-46. Epub 2006 Aug 4.

16.

Direct medical costs of COPD--an excess cost approach based on two population-based studies.

Menn P, Heinrich J, Huber RM, Jörres RA, John J, Karrasch S, Peters A, Schulz H, Holle R; KORA Study Group..

Respir Med. 2012 Apr;106(4):540-8. doi: 10.1016/j.rmed.2011.10.013. Epub 2011 Nov 18.

17.

The burden of COPD in Italy: results from the Confronting COPD survey.

Dal Negro R, Rossi A, Cerveri I.

Respir Med. 2003 Mar;97 Suppl C:S43-50.

PMID:
12647942
18.

[Relationship between disease severity, smoking index age and direct costs of hospital treatment of COPD exacerbations].

Targowski T, Jahnz-Rózyk K, From S, Płusa T.

Pneumonol Alergol Pol. 2005;73(1):32-5. Polish.

PMID:
16539181
19.

The cost of moderate and severe COPD exacerbations to the Canadian healthcare system.

Mittmann N, Kuramoto L, Seung SJ, Haddon JM, Bradley-Kennedy C, Fitzgerald JM.

Respir Med. 2008 Mar;102(3):413-21. Epub 2007 Dec 20.

20.

Supplemental Content

Support Center